Global Metabolic Disease Treatment Market
Global Metabolic Disease Treatment Market

Metabolic Disease Treatment Comprehensive Study by Type (Glycogen Metabolism Disease Drug, Lipid Metabolism Disease Drug, Amino Acid Metabolism Drug), Application (Hospital, Retail Pharmacy), Route of Administration (Inhalation, Injection, Other) Players and Region - Global Market Outlook to 2026

Metabolic Disease Treatment Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Feb 2021 Edition 208 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Metabolic Disease Treatment Market Overview:
Metabolism Drugs is used to treat the metabolic disease in humans. Metabolic disease mainly covers Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism, Metal Metabolism Disease, etc. A metabolic disorder occurs when abnormal chemical reactions in the body disrupt the body process. Increasing incidences of Inherited metabolic diseases due to changing lifestyles and rising number of diabetic patients boosting the metabolic disease treatment market. Some of the players profiled in the study are Merck & Co., Inc (United States), Novartis International AG (Switzerland), Takeda Pharmaceutical Company Limited (Japan), AstraZeneca plc (United Kingdom), C.H. Boehringer Sohn AG & Ko. KG (Germany), Kowa Pharmaceuticals America, Inc (United States), LG Life Science (South Korea) and Mitsubishi Tanabe Pharma Corporation (Japan).

On the basis of geography, the market of Metabolic Disease Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Route of Administration, the sub-segment i.e. Inhalation will boost the Metabolic Disease Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Growth Drivers
  • Increasing incidences of Inherited Metabolic Diseases due to Changing Lifestyles
  • Rising Number of Diabetic Patients

Influencing Trend
  • Advancements in Drug Delivery Technologies

Restraints
  • Straight Government Regulation Related to Drug Production

Opportunities
  • High Healthcare Expenditure and Raising Awareness about Metabolic Disease in Developing Countries
  • Growing Healthcare Infrastructure in the Developing Economies

Challenges
  • Side Effects of the Drugs




The global metabolic disease treatment market is fragmented with numerous market players. Due to the rising drug approvals, mid-size to smaller companies are increasing their market presence by introducing new ingredients with fewer prices.

Target Audience:
Metabolic Disease Treatment Drugs Manufacturers, Metabolic Disorders Drugs Suppliers, Medical Research Laboratories, Research and Development (R&D) Companies, Market Research and Consulting Service Providers, Potential Investors and Others

Major Objectives Focused through this Study
• To define, describe, and forecast the Global Metabolic Disease Treatment market on the basis of product [Glycogen Metabolism Disease Drug, Lipid Metabolism Disease Drug and Amino Acid Metabolism Drug] , application [Hospital and Retail Pharmacy], key regions and end user
• To provide in-depth information regarding major influencing factors affecting the growth of the market (trends, drivers, restraints, opportunities, and industry-centric and regional challenges)
• To strategically analyse the micro-markets and important business segments with respect to individual growth drivers , market trends and potential, and historical contributions to the total market
• Identifying the opportunities in the market for key stakeholders and detailing the competitive landscape for market leaders
• To provide market size for various segments of the Metabolic Disease Treatment market with respect to major geographies, namely, South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico)
• To strategically profile the key players and analyzing their market shares and core competencies in the Metabolic Disease Treatment industry
• To track key developments such as product launches, expansions, agreements, partnerships, mergers & acquisitions, and R&D activities that are key factors in shaping the market

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**. Additionally, the Players which are also part of the research are .
** Confirmation on availability of data would be informed prior purchase

While framing the research framework, major and emerging players operating in the Metabolic Disease Treatment market in various regions have been profiled, and their offerings, geographic footprints, and distribution/sales channels have been analysed through in-depth discussions. The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.
Report Objectives / Segmentation Covered
By Type
  • Glycogen Metabolism Disease Drug
  • Lipid Metabolism Disease Drug
  • Amino Acid Metabolism Drug
By Application
  • Hospital
  • Retail Pharmacy
By Route of Administration
  • Inhalation
  • Injection
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing incidences of Inherited Metabolic Diseases due to Changing Lifestyles
      • 3.2.2. Rising Number of Diabetic Patients
    • 3.3. Market Challenges
      • 3.3.1. Side Effects of the Drugs
    • 3.4. Market Trends
      • 3.4.1. Advancements in Drug Delivery Technologies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Metabolic Disease Treatment, by Type, Application, Route of Administration and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Metabolic Disease Treatment (Value)
      • 5.2.1. Global Metabolic Disease Treatment by: Type (Value)
        • 5.2.1.1. Glycogen Metabolism Disease Drug
        • 5.2.1.2. Lipid Metabolism Disease Drug
        • 5.2.1.3. Amino Acid Metabolism Drug
      • 5.2.2. Global Metabolic Disease Treatment by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Retail Pharmacy
      • 5.2.3. Global Metabolic Disease Treatment by: Route of Administration (Value)
        • 5.2.3.1. Inhalation
        • 5.2.3.2. Injection
        • 5.2.3.3. Other
      • 5.2.4. Global Metabolic Disease Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Metabolic Disease Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Merck & Co., Inc (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis International AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Takeda Pharmaceutical Company Limited (Japan)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. AstraZeneca plc (United Kingdom)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. C.H. Boehringer Sohn AG & Ko. KG (Germany)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Kowa Pharmaceuticals America, Inc (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. LG Life Science (South Korea)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Mitsubishi Tanabe Pharma Corporation (Japan)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Metabolic Disease Treatment Sale, by Type, Application, Route of Administration and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Metabolic Disease Treatment (Value)
      • 7.2.1. Global Metabolic Disease Treatment by: Type (Value)
        • 7.2.1.1. Glycogen Metabolism Disease Drug
        • 7.2.1.2. Lipid Metabolism Disease Drug
        • 7.2.1.3. Amino Acid Metabolism Drug
      • 7.2.2. Global Metabolic Disease Treatment by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Retail Pharmacy
      • 7.2.3. Global Metabolic Disease Treatment by: Route of Administration (Value)
        • 7.2.3.1. Inhalation
        • 7.2.3.2. Injection
        • 7.2.3.3. Other
      • 7.2.4. Global Metabolic Disease Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Metabolic Disease Treatment: by Type(USD Million)
  • Table 2. Metabolic Disease Treatment Glycogen Metabolism Disease Drug , by Region USD Million (2015-2020)
  • Table 3. Metabolic Disease Treatment Lipid Metabolism Disease Drug , by Region USD Million (2015-2020)
  • Table 4. Metabolic Disease Treatment Amino Acid Metabolism Drug , by Region USD Million (2015-2020)
  • Table 5. Metabolic Disease Treatment: by Application(USD Million)
  • Table 6. Metabolic Disease Treatment Hospital , by Region USD Million (2015-2020)
  • Table 7. Metabolic Disease Treatment Retail Pharmacy , by Region USD Million (2015-2020)
  • Table 8. Metabolic Disease Treatment: by Route of Administration(USD Million)
  • Table 9. Metabolic Disease Treatment Inhalation , by Region USD Million (2015-2020)
  • Table 10. Metabolic Disease Treatment Injection , by Region USD Million (2015-2020)
  • Table 11. Metabolic Disease Treatment Other , by Region USD Million (2015-2020)
  • Table 12. South America Metabolic Disease Treatment, by Country USD Million (2015-2020)
  • Table 13. South America Metabolic Disease Treatment, by Type USD Million (2015-2020)
  • Table 14. South America Metabolic Disease Treatment, by Application USD Million (2015-2020)
  • Table 15. South America Metabolic Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 16. Brazil Metabolic Disease Treatment, by Type USD Million (2015-2020)
  • Table 17. Brazil Metabolic Disease Treatment, by Application USD Million (2015-2020)
  • Table 18. Brazil Metabolic Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 19. Argentina Metabolic Disease Treatment, by Type USD Million (2015-2020)
  • Table 20. Argentina Metabolic Disease Treatment, by Application USD Million (2015-2020)
  • Table 21. Argentina Metabolic Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 22. Rest of South America Metabolic Disease Treatment, by Type USD Million (2015-2020)
  • Table 23. Rest of South America Metabolic Disease Treatment, by Application USD Million (2015-2020)
  • Table 24. Rest of South America Metabolic Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 25. Asia Pacific Metabolic Disease Treatment, by Country USD Million (2015-2020)
  • Table 26. Asia Pacific Metabolic Disease Treatment, by Type USD Million (2015-2020)
  • Table 27. Asia Pacific Metabolic Disease Treatment, by Application USD Million (2015-2020)
  • Table 28. Asia Pacific Metabolic Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 29. China Metabolic Disease Treatment, by Type USD Million (2015-2020)
  • Table 30. China Metabolic Disease Treatment, by Application USD Million (2015-2020)
  • Table 31. China Metabolic Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 32. Japan Metabolic Disease Treatment, by Type USD Million (2015-2020)
  • Table 33. Japan Metabolic Disease Treatment, by Application USD Million (2015-2020)
  • Table 34. Japan Metabolic Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 35. India Metabolic Disease Treatment, by Type USD Million (2015-2020)
  • Table 36. India Metabolic Disease Treatment, by Application USD Million (2015-2020)
  • Table 37. India Metabolic Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 38. South Korea Metabolic Disease Treatment, by Type USD Million (2015-2020)
  • Table 39. South Korea Metabolic Disease Treatment, by Application USD Million (2015-2020)
  • Table 40. South Korea Metabolic Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 41. Taiwan Metabolic Disease Treatment, by Type USD Million (2015-2020)
  • Table 42. Taiwan Metabolic Disease Treatment, by Application USD Million (2015-2020)
  • Table 43. Taiwan Metabolic Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 44. Australia Metabolic Disease Treatment, by Type USD Million (2015-2020)
  • Table 45. Australia Metabolic Disease Treatment, by Application USD Million (2015-2020)
  • Table 46. Australia Metabolic Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 47. Rest of Asia-Pacific Metabolic Disease Treatment, by Type USD Million (2015-2020)
  • Table 48. Rest of Asia-Pacific Metabolic Disease Treatment, by Application USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Metabolic Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 50. Europe Metabolic Disease Treatment, by Country USD Million (2015-2020)
  • Table 51. Europe Metabolic Disease Treatment, by Type USD Million (2015-2020)
  • Table 52. Europe Metabolic Disease Treatment, by Application USD Million (2015-2020)
  • Table 53. Europe Metabolic Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 54. Germany Metabolic Disease Treatment, by Type USD Million (2015-2020)
  • Table 55. Germany Metabolic Disease Treatment, by Application USD Million (2015-2020)
  • Table 56. Germany Metabolic Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 57. France Metabolic Disease Treatment, by Type USD Million (2015-2020)
  • Table 58. France Metabolic Disease Treatment, by Application USD Million (2015-2020)
  • Table 59. France Metabolic Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 60. Italy Metabolic Disease Treatment, by Type USD Million (2015-2020)
  • Table 61. Italy Metabolic Disease Treatment, by Application USD Million (2015-2020)
  • Table 62. Italy Metabolic Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 63. United Kingdom Metabolic Disease Treatment, by Type USD Million (2015-2020)
  • Table 64. United Kingdom Metabolic Disease Treatment, by Application USD Million (2015-2020)
  • Table 65. United Kingdom Metabolic Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 66. Netherlands Metabolic Disease Treatment, by Type USD Million (2015-2020)
  • Table 67. Netherlands Metabolic Disease Treatment, by Application USD Million (2015-2020)
  • Table 68. Netherlands Metabolic Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 69. Rest of Europe Metabolic Disease Treatment, by Type USD Million (2015-2020)
  • Table 70. Rest of Europe Metabolic Disease Treatment, by Application USD Million (2015-2020)
  • Table 71. Rest of Europe Metabolic Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 72. MEA Metabolic Disease Treatment, by Country USD Million (2015-2020)
  • Table 73. MEA Metabolic Disease Treatment, by Type USD Million (2015-2020)
  • Table 74. MEA Metabolic Disease Treatment, by Application USD Million (2015-2020)
  • Table 75. MEA Metabolic Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 76. Middle East Metabolic Disease Treatment, by Type USD Million (2015-2020)
  • Table 77. Middle East Metabolic Disease Treatment, by Application USD Million (2015-2020)
  • Table 78. Middle East Metabolic Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 79. Africa Metabolic Disease Treatment, by Type USD Million (2015-2020)
  • Table 80. Africa Metabolic Disease Treatment, by Application USD Million (2015-2020)
  • Table 81. Africa Metabolic Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 82. North America Metabolic Disease Treatment, by Country USD Million (2015-2020)
  • Table 83. North America Metabolic Disease Treatment, by Type USD Million (2015-2020)
  • Table 84. North America Metabolic Disease Treatment, by Application USD Million (2015-2020)
  • Table 85. North America Metabolic Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 86. United States Metabolic Disease Treatment, by Type USD Million (2015-2020)
  • Table 87. United States Metabolic Disease Treatment, by Application USD Million (2015-2020)
  • Table 88. United States Metabolic Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 89. Canada Metabolic Disease Treatment, by Type USD Million (2015-2020)
  • Table 90. Canada Metabolic Disease Treatment, by Application USD Million (2015-2020)
  • Table 91. Canada Metabolic Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 92. Mexico Metabolic Disease Treatment, by Type USD Million (2015-2020)
  • Table 93. Mexico Metabolic Disease Treatment, by Application USD Million (2015-2020)
  • Table 94. Mexico Metabolic Disease Treatment, by Route of Administration USD Million (2015-2020)
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Metabolic Disease Treatment: by Type(USD Million)
  • Table 104. Metabolic Disease Treatment Glycogen Metabolism Disease Drug , by Region USD Million (2021-2026)
  • Table 105. Metabolic Disease Treatment Lipid Metabolism Disease Drug , by Region USD Million (2021-2026)
  • Table 106. Metabolic Disease Treatment Amino Acid Metabolism Drug , by Region USD Million (2021-2026)
  • Table 107. Metabolic Disease Treatment: by Application(USD Million)
  • Table 108. Metabolic Disease Treatment Hospital , by Region USD Million (2021-2026)
  • Table 109. Metabolic Disease Treatment Retail Pharmacy , by Region USD Million (2021-2026)
  • Table 110. Metabolic Disease Treatment: by Route of Administration(USD Million)
  • Table 111. Metabolic Disease Treatment Inhalation , by Region USD Million (2021-2026)
  • Table 112. Metabolic Disease Treatment Injection , by Region USD Million (2021-2026)
  • Table 113. Metabolic Disease Treatment Other , by Region USD Million (2021-2026)
  • Table 114. South America Metabolic Disease Treatment, by Country USD Million (2021-2026)
  • Table 115. South America Metabolic Disease Treatment, by Type USD Million (2021-2026)
  • Table 116. South America Metabolic Disease Treatment, by Application USD Million (2021-2026)
  • Table 117. South America Metabolic Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 118. Brazil Metabolic Disease Treatment, by Type USD Million (2021-2026)
  • Table 119. Brazil Metabolic Disease Treatment, by Application USD Million (2021-2026)
  • Table 120. Brazil Metabolic Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 121. Argentina Metabolic Disease Treatment, by Type USD Million (2021-2026)
  • Table 122. Argentina Metabolic Disease Treatment, by Application USD Million (2021-2026)
  • Table 123. Argentina Metabolic Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 124. Rest of South America Metabolic Disease Treatment, by Type USD Million (2021-2026)
  • Table 125. Rest of South America Metabolic Disease Treatment, by Application USD Million (2021-2026)
  • Table 126. Rest of South America Metabolic Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 127. Asia Pacific Metabolic Disease Treatment, by Country USD Million (2021-2026)
  • Table 128. Asia Pacific Metabolic Disease Treatment, by Type USD Million (2021-2026)
  • Table 129. Asia Pacific Metabolic Disease Treatment, by Application USD Million (2021-2026)
  • Table 130. Asia Pacific Metabolic Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 131. China Metabolic Disease Treatment, by Type USD Million (2021-2026)
  • Table 132. China Metabolic Disease Treatment, by Application USD Million (2021-2026)
  • Table 133. China Metabolic Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 134. Japan Metabolic Disease Treatment, by Type USD Million (2021-2026)
  • Table 135. Japan Metabolic Disease Treatment, by Application USD Million (2021-2026)
  • Table 136. Japan Metabolic Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 137. India Metabolic Disease Treatment, by Type USD Million (2021-2026)
  • Table 138. India Metabolic Disease Treatment, by Application USD Million (2021-2026)
  • Table 139. India Metabolic Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 140. South Korea Metabolic Disease Treatment, by Type USD Million (2021-2026)
  • Table 141. South Korea Metabolic Disease Treatment, by Application USD Million (2021-2026)
  • Table 142. South Korea Metabolic Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 143. Taiwan Metabolic Disease Treatment, by Type USD Million (2021-2026)
  • Table 144. Taiwan Metabolic Disease Treatment, by Application USD Million (2021-2026)
  • Table 145. Taiwan Metabolic Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 146. Australia Metabolic Disease Treatment, by Type USD Million (2021-2026)
  • Table 147. Australia Metabolic Disease Treatment, by Application USD Million (2021-2026)
  • Table 148. Australia Metabolic Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 149. Rest of Asia-Pacific Metabolic Disease Treatment, by Type USD Million (2021-2026)
  • Table 150. Rest of Asia-Pacific Metabolic Disease Treatment, by Application USD Million (2021-2026)
  • Table 151. Rest of Asia-Pacific Metabolic Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 152. Europe Metabolic Disease Treatment, by Country USD Million (2021-2026)
  • Table 153. Europe Metabolic Disease Treatment, by Type USD Million (2021-2026)
  • Table 154. Europe Metabolic Disease Treatment, by Application USD Million (2021-2026)
  • Table 155. Europe Metabolic Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 156. Germany Metabolic Disease Treatment, by Type USD Million (2021-2026)
  • Table 157. Germany Metabolic Disease Treatment, by Application USD Million (2021-2026)
  • Table 158. Germany Metabolic Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 159. France Metabolic Disease Treatment, by Type USD Million (2021-2026)
  • Table 160. France Metabolic Disease Treatment, by Application USD Million (2021-2026)
  • Table 161. France Metabolic Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 162. Italy Metabolic Disease Treatment, by Type USD Million (2021-2026)
  • Table 163. Italy Metabolic Disease Treatment, by Application USD Million (2021-2026)
  • Table 164. Italy Metabolic Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 165. United Kingdom Metabolic Disease Treatment, by Type USD Million (2021-2026)
  • Table 166. United Kingdom Metabolic Disease Treatment, by Application USD Million (2021-2026)
  • Table 167. United Kingdom Metabolic Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 168. Netherlands Metabolic Disease Treatment, by Type USD Million (2021-2026)
  • Table 169. Netherlands Metabolic Disease Treatment, by Application USD Million (2021-2026)
  • Table 170. Netherlands Metabolic Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 171. Rest of Europe Metabolic Disease Treatment, by Type USD Million (2021-2026)
  • Table 172. Rest of Europe Metabolic Disease Treatment, by Application USD Million (2021-2026)
  • Table 173. Rest of Europe Metabolic Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 174. MEA Metabolic Disease Treatment, by Country USD Million (2021-2026)
  • Table 175. MEA Metabolic Disease Treatment, by Type USD Million (2021-2026)
  • Table 176. MEA Metabolic Disease Treatment, by Application USD Million (2021-2026)
  • Table 177. MEA Metabolic Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 178. Middle East Metabolic Disease Treatment, by Type USD Million (2021-2026)
  • Table 179. Middle East Metabolic Disease Treatment, by Application USD Million (2021-2026)
  • Table 180. Middle East Metabolic Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 181. Africa Metabolic Disease Treatment, by Type USD Million (2021-2026)
  • Table 182. Africa Metabolic Disease Treatment, by Application USD Million (2021-2026)
  • Table 183. Africa Metabolic Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 184. North America Metabolic Disease Treatment, by Country USD Million (2021-2026)
  • Table 185. North America Metabolic Disease Treatment, by Type USD Million (2021-2026)
  • Table 186. North America Metabolic Disease Treatment, by Application USD Million (2021-2026)
  • Table 187. North America Metabolic Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 188. United States Metabolic Disease Treatment, by Type USD Million (2021-2026)
  • Table 189. United States Metabolic Disease Treatment, by Application USD Million (2021-2026)
  • Table 190. United States Metabolic Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 191. Canada Metabolic Disease Treatment, by Type USD Million (2021-2026)
  • Table 192. Canada Metabolic Disease Treatment, by Application USD Million (2021-2026)
  • Table 193. Canada Metabolic Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 194. Mexico Metabolic Disease Treatment, by Type USD Million (2021-2026)
  • Table 195. Mexico Metabolic Disease Treatment, by Application USD Million (2021-2026)
  • Table 196. Mexico Metabolic Disease Treatment, by Route of Administration USD Million (2021-2026)
  • Table 197. Research Programs/Design for This Report
  • Table 198. Key Data Information from Secondary Sources
  • Table 199. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Metabolic Disease Treatment: by Type USD Million (2015-2020)
  • Figure 5. Global Metabolic Disease Treatment: by Application USD Million (2015-2020)
  • Figure 6. Global Metabolic Disease Treatment: by Route of Administration USD Million (2015-2020)
  • Figure 7. South America Metabolic Disease Treatment Share (%), by Country
  • Figure 8. Asia Pacific Metabolic Disease Treatment Share (%), by Country
  • Figure 9. Europe Metabolic Disease Treatment Share (%), by Country
  • Figure 10. MEA Metabolic Disease Treatment Share (%), by Country
  • Figure 11. North America Metabolic Disease Treatment Share (%), by Country
  • Figure 12. Global Metabolic Disease Treatment share by Players 2020 (%)
  • Figure 13. Global Metabolic Disease Treatment share by Players (Top 3) 2020(%)
  • Figure 14. Global Metabolic Disease Treatment share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Merck & Co., Inc (United States) Revenue, Net Income and Gross profit
  • Figure 17. Merck & Co., Inc (United States) Revenue: by Geography 2020
  • Figure 18. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. Novartis International AG (Switzerland) Revenue: by Geography 2020
  • Figure 20. Takeda Pharmaceutical Company Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 21. Takeda Pharmaceutical Company Limited (Japan) Revenue: by Geography 2020
  • Figure 22. AstraZeneca plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 23. AstraZeneca plc (United Kingdom) Revenue: by Geography 2020
  • Figure 24. C.H. Boehringer Sohn AG & Ko. KG (Germany) Revenue, Net Income and Gross profit
  • Figure 25. C.H. Boehringer Sohn AG & Ko. KG (Germany) Revenue: by Geography 2020
  • Figure 26. Kowa Pharmaceuticals America, Inc (United States) Revenue, Net Income and Gross profit
  • Figure 27. Kowa Pharmaceuticals America, Inc (United States) Revenue: by Geography 2020
  • Figure 28. LG Life Science (South Korea) Revenue, Net Income and Gross profit
  • Figure 29. LG Life Science (South Korea) Revenue: by Geography 2020
  • Figure 30. Mitsubishi Tanabe Pharma Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 31. Mitsubishi Tanabe Pharma Corporation (Japan) Revenue: by Geography 2020
  • Figure 32. Global Metabolic Disease Treatment: by Type USD Million (2021-2026)
  • Figure 33. Global Metabolic Disease Treatment: by Application USD Million (2021-2026)
  • Figure 34. Global Metabolic Disease Treatment: by Route of Administration USD Million (2021-2026)
  • Figure 35. South America Metabolic Disease Treatment Share (%), by Country
  • Figure 36. Asia Pacific Metabolic Disease Treatment Share (%), by Country
  • Figure 37. Europe Metabolic Disease Treatment Share (%), by Country
  • Figure 38. MEA Metabolic Disease Treatment Share (%), by Country
  • Figure 39. North America Metabolic Disease Treatment Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Merck & Co., Inc (United States)
  • Novartis International AG (Switzerland)
  • Takeda Pharmaceutical Company Limited (Japan)
  • AstraZeneca plc (United Kingdom)
  • C.H. Boehringer Sohn AG & Ko. KG (Germany)
  • Kowa Pharmaceuticals America, Inc (United States)
  • LG Life Science (South Korea)
  • Mitsubishi Tanabe Pharma Corporation (Japan)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation